



Abridged Financial Statements

Beacon Medical Distribution Limited

For the financial year ended 30 June 2025

Registered number: 713392

Company Information

Directors	Michael Cullen Pauline Cullen
Company secretary	Pauline Cullen
Registered number	713392
Registered office	Beacon Care Fertility Limited 1st Floor, Concourse Building Beacon Mall Sandyford Dublin 18 D18 P6N4 Ireland
Independent auditor	Grant Thornton Chartered Accountants & Statutory Audit Firm 13-18 City Quay Dublin 2 Ireland
Bankers	AIB Unit 33 Blackthorn Road Sandyford Business Park Dublin 18 Ireland
Solicitors	Keoghs Ireland LLP 15 Upper Fitzwilliam St Dublin 2 Ireland

Contents

	Page
Special auditor's report	1 - 4
Abridged statement of financial position	5
Notes to the abridged financial statements	6 - 12



Independent auditor's special report to the directors of Beacon Medical Distribution Limited pursuant to section 356 of the Companies Act 2014

Opinion

In our opinion, the directors are entitled under section 352 of the Companies Act 2014 to annex abridged financial statements to the annual return of Beacon Medical Distribution Limited ("the Company") and those abridged financial statements have been properly prepared pursuant to the provisions of section 353 of that Act (exemptions available to small companies).

Basis of opinion

We have examined:

- (i) the abridged financial statements for the financial year ended 30 June 2025 on pages 5 to 12 which the directors of Beacon Medical Distribution Limited propose to annex to the Annual return of the Company; and
- (ii) the financial statements to be laid before the Annual general meeting which form the basis for those abridged financial statements.

The scope of our work for the purpose of this report was limited to confirming that the directors are entitled to annex abridged financial statements to the annual return and that those abridged financial statements have been properly prepared, pursuant to section 353 of the Companies Act 2014, from the financial statements to be laid before the Annual General Meeting.

Other information

On 7 Jan 2026 we reported, as auditor of the Company, to the members on the financial statements for the financial year ended 30 June 2025, and the full text of our audit report is reproduced below.

Michael Shelley
for and on behalf of

A handwritten signature in blue ink, appearing to read "Michael Shelley", written over a horizontal line.

Grant Thornton
Chartered Accountants &
Statutory Audit Firm
13-18 City Quay
Dublin 2
Ireland
Date: 7 January 2026

Independent auditor's special report to the directors of Beacon Medical Distribution Limited pursuant to section 356 of the Companies Act 2014

Opinion

We have audited the financial statements of Beacon Medical Distribution Limited (the 'Company'), which comprise the Statement of comprehensive income, the Statement of financial position, the Statement of changes in equity for the financial year ended 30 June 2025, and the related notes to the financial statements, including the summary of significant accounting policies.

The financial reporting framework that has been applied in the preparation of the financial statements is Irish law and accounting standards issued by the Financial Reporting Council including FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (Generally Accepted Accounting Practice in Ireland) (the "relevant accounting framework").

In our opinion, Beacon Medical Distribution Limited's financial statements:

- give a true and fair view of the assets, liabilities and financial position of the Company as at 30 June 2025 and of its profit or loss for the financial year then ended;
- have been properly prepared in accordance with the relevant accounting framework; and
- have been properly prepared in accordance with the requirements of the Companies Act 2014.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (Ireland) (ISAs (Ireland)) and applicable law. Our responsibilities under those standards are further described in the 'Auditor's responsibilities for the audit of the financial statements' section of our report. We are independent of the Company in accordance with the ethical requirements that are relevant to our audit of financial statements in Ireland, including the Ethical Standard for Auditors (Ireland) issued by the Irish Auditing and Accounting Supervisory Authority (IAASA), and the ethical pronouncements established by Chartered Accountants Ireland, applied as determined to be appropriate in the circumstances for the entity. We have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Company's ability to continue as a going concern for a period of at least twelve months from the date when the financial statements are authorised for issue.

Our responsibilities, and the responsibilities of the directors, with respect to going concern are described in the relevant sections of this report.



Independent auditor's special report to the directors of Beacon Medical Distribution Limited pursuant to section 356 of the Companies Act 2014 (continued)

Other information

The directors are responsible for the other information. Other information comprises information included in the Annual Report, other than the financial statements and our auditor's report thereon, including the Directors' report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinion on the matters prescribed by the Companies Act 2014

We have obtained all the information and explanations which to the best of our knowledge and belief, we considered necessary for the purposes of our audit.

In our opinion:

- the accounting records of the Company were sufficient to permit the financial statements to be readily and properly audited.

The Abridged statement of financial position and the Statement of comprehensive income are in agreement with the accounting records and returns.

In our opinion, based on the work undertaken in the course of our audit:

- the information given in the Directors' report for the financial year is consistent with the financial statements;
- the Directors' report has been prepared in accordance with applicable legal requirements, excluding the requirements on sustainability reporting in Part 28.

Based on our knowledge and understanding of the Company and its environment obtained in the course of the audit, we have not identified any material misstatements in the Directors' report.

Matters on which we are required to report by exception

The Companies Act 2014 requires us to report to you if, in our opinion, the requirements of sections 305 to 312 of the Act, which relate to the disclosure of directors' remuneration and transactions with directors have not been complied with by the Company. We have nothing to report in this regard.



Independent auditor's special report to the directors of Beacon Medical Distribution Limited pursuant to section 356 of the Companies Act 2014 (continued)

Responsibilities of management and those charged with governance for the financial statements

As explained more fully in the directors' responsibilities statement, management is responsible for the preparation of the financial statements which give a true and fair view in accordance with Generally Accepted Accounting Practice in Ireland, including FRS102, and for such internal control as they determine necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's financial reporting process and for the preparation of financial statements that give a true and fair view.

Auditor's responsibilities for the audit of the financial statements

The objectives of an auditor are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (Ireland) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the Irish Auditing and Accounting Supervisory Authority's website at: http://www.iaasa.ie/getmedia/b2389013-1cf6-458b-9b8f-a98202dc9c3a/Description_of_auditors_responsibilities_for_audit.pdf. This description forms part of our auditor's report.

The purpose of our audit work and to whom we owe our responsibilities

This report is made solely to the Company's members, as a body, in accordance with section 391 of the Companies Act 2014. Our audit work has been undertaken so that we might state to the Company's members those matters we are required to state to them in an auditor's report and for no other purpose.

To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and the Company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Michael Shelley
for and on behalf of

A handwritten signature in black ink, appearing to read "Michael Shelley".

Grant Thornton
Chartered Accountants &
Statutory Audit Firm
13-18 City Quay
Dublin 2
Ireland
Date: 7 January 2026

Abridged statement of financial position

As at 30 June 2025

	Note	2025 €	2024 €
Current assets			
Stocks	5	17,762	2,897
Debtors: amounts falling due within one year	6	55,268	124,426
Cash at bank and in hand	7	76,437	41,058
		<u>149,467</u>	<u>168,381</u>
Current liabilities			
Creditors: amounts falling due within one year	8	(15,859)	(20,004)
		<u>133,608</u>	<u>148,377</u>
Net current assets		<u>133,608</u>	<u>148,377</u>
Net assets		<u>133,608</u>	<u>148,377</u>
Equity			
Share capital	9,10	100	100
Accumulate profit	10	133,508	148,277
Total equity		<u>133,608</u>	<u>148,377</u>

We, as directors of Beacon Medical Distribution Limited, state that:

The Company has relied on the specific exemptions contained in section 352 of the Companies Act 2014; the Company has done so on the grounds that it is entitled to the benefit of that exemption as a small Company and the abridged financial statements have been properly prepared in accordance with section 353 of the Companies Act 2014.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A for small entities.

The financial statements were approved and authorised for issue by the board:

Michael Cullen
Director

Pauline Cullen
Director

Date:

The notes on pages 6 to 12 form part of these financial statements.

6 January 2026

Notes to the abridged financial statements

For the financial year ended 30 June 2025

1. General information

Beacon Medical Distribution Limited (“the Company”) is a private company limited by shares and incorporated in 9 February 2022, domiciled and registered in Ireland. The registered number of the company is 713392 and the address of its registered office is 1st Floor, Concourse Building, Beacon Mall, Sandyford, Dublin 18, D19 P6N4, Ireland.

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and Irish statute comprising of the Companies Act 2014.

The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgement in applying the Company's accounting policies (see note 3).

The Company qualifies as a small company as defined by section 280A of the Act, in respect of the financial year and has applied the rules of the ‘Small Companies Regime’ in accordance with section 280C of the Act and section 1A of FRS 102.

The financial statements are presented in Euro (€).

The following principal accounting policies have been applied:

2.2 Going concern

As at 30 June 2025, the Company had net assets of €133,608 (2024: €148,377). Furthermore, the Company has net loss of €(14,769) (2024: €84,847), therefore accumulating earnings of €133,508 (2024: €148,848), sufficient to cover its capital.

The directors have reviewed the cash flows for the Company for a period of at least 12 months from the date of signing the financial statements. Based on that review, the Directors are satisfied that the Company will be able to meet their liabilities as the fall due for the foreseeable future; that is at least 12 months from the date of approval of these financial statements.

Accordingly, the directors feel it appropriate to continue to adopt the going concern basis of accounting.

Notes to the abridged financial statements

For the financial year ended 30 June 2025

2. Accounting policies (continued)

2.3 Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Sale of goods

Revenue from the sale of goods is recognised when all of the following conditions are satisfied:

- the Company has transferred the significant risks and rewards of ownership to the buyer;
- the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
- the amount of revenue can be measured reliably;
- it is probable that the Company will receive the consideration due under the transaction; and
- the costs incurred or to be incurred in respect of the transaction can be measured reliably.

2.4 Provisions for liabilities

Provisions are made where an event has taken place that gives the company a legal or constructive obligation that probably requires settlement by a transfer of economic benefit, and a reliable estimate can be made of the amount of the obligation.

Provisions are charged as an expense to the Statement of comprehensive income in the year that the company becomes aware of the obligation, and are measured at the best estimate at the Statement of financial position date of the expenditure required to settle the obligation, taking into account relevant risks and uncertainties.

When payments are eventually made, they are charges to the provision carried in the Statement of financial position.

2.5 Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company operates and generates income.

Notes to the abridged financial statements

For the financial year ended 30 June 2025

2. Accounting policies (continued)

2.6 Stocks

Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to sell. Cost is based on the cost of purchase on a first in, first out basis.

At each reporting date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs sell. The impairment loss is recognised immediately in Statement of comprehensive income

2.7 Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

2.8 Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours.

2.9 Creditors

Short-term creditors are measured at the transaction price.

2.10 Financial instruments

The Company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors.

Debt instruments (other than those wholly repayable or receivable within one year), including loans and other accounts receivable and payable, are initially measured at present value of the future cash flows and subsequently at amortised cost using the effective interest method. Debt instruments that are payable or receivable within one year, typically trade debtors and creditors, are measured, initially and subsequently, at the undiscounted amount of the cash or other consideration expected to be paid or received. However, if the arrangements of a short-term instrument constitute a financing transaction, like the payment of a trade debt deferred beyond normal business terms or in case of an out-right short-term loan that is not at market rate, the financial asset or liability is measured, initially at the present value of future cash flows discounted at a market rate of interest for a similar debt instrument and subsequently at amortised cost.

Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the Statement of comprehensive income.

For financial assets measured at amortised cost, the impairment loss is measured as the difference between an asset's carrying amount and the present value of estimated cash flows discounted at the asset's original effective interest rate. If a financial asset has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract.

Notes to the abridged financial statements

For the financial year ended 30 June 2025

2. Accounting policies (continued)

2.10 Financial instruments (continued)

For financial assets measured at cost less impairment, the impairment loss is measured as the difference between an asset's carrying amount and best estimate of the recoverable amount, which is an approximation of the amount that the Company would receive for the asset if it were to be sold at the reporting date.

Financial assets and liabilities are offset and the net amount reported in the Statement of financial position when there is an enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

3. Judgements in applying accounting policies and key sources of estimation uncertainty

Preparation of financial statements pursuant to FRS 102 requires estimates to be made. These impact on the profit and loss account and the valuation of assets and liabilities in the balance sheet. Such estimates and judgements are based on historical experience and other factors including expectation of future events that are believed to be reasonable under the circumstances and are subject to continual re-evaluation.

Recoverability of debtors

Debtors arising out of operations are considered by the directors to have a low credit risks. The directors consider that the outstanding carrying amounts of debtors approximates to their value. The bad debt provision for the financial year ended 30 June 2025 is €2,732 (2024: €2,732).

4. Employees

The Company has one employee other than the directors, who did not receive any remuneration (2024: €Nil).

5. Stocks

	2025	2024
	€	€
Goods for resale	17,762	2,897

Notes to the abridged financial statements

For the financial year ended 30 June 2025

6. Debtors

	2025 €	2024 €
Trade debtors	30,961	19,704
Amounts owed by related party	-	93,458
Prepayments	11,788	11,264
Tax recoverable	12,519	-
	<u>55,268</u>	<u>124,426</u>

Amounts owed by group undertakings and related parties are non-interest bearing and repayable on demand.

The Company provided bad debt provision amounted to €Nil during the financial year ended 30 June 2025 (2024: €2,732).

7. Cash and cash equivalents

	2025 €	2024 €
Cash at bank and in hand	<u>76,437</u>	<u>41,058</u>

8. Creditors: Amounts falling due within one year

	2025 €	2024 €
Trade creditors	8,737	1,095
Corporation tax	-	4,027
Taxation and social insurance	7,122	14,882
	<u>15,859</u>	<u>20,004</u>

Trade creditors are payable at various dates in the next 3 months in accordance with the supplier's usual and customary credit terms.

Notes to the abridged financial statements

For the financial year ended 30 June 2025

9. Share capital

	2025 €	2024 €
Authorised		
1,000,000 (2024: 1,000,000) Ordinary shares of €1.00 each	<u>1,000,000</u>	<u>1,000,000</u>
Allotted, called up and fully paid		
100 (2024: 100) Ordinary shares of €1.00 each	<u>100</u>	<u>100</u>

10. Reserves

Share capital

Share capital represents the nominal value of shares that have been issued.

Accumulated profit

Accumulated profit reserve represents cumulative profits and losses net of dividends paid and other adjustments.

11. Appropriation of Profit and loss account

	2025 €	2024 €
Profit and loss account brought forward at the beginning of the financial year	148,277	63,430
(Loss)/profit for the financial year	<u>(14,769)</u>	<u>84,847</u>
Profit and loss account carried forward at the end of the financial year	<u><u>133,508</u></u>	<u><u>148,277</u></u>

12. Post balance sheet events

No significant events taken place since the year end that would result in adjustment to the financial statements or inclusion of a note thereto.

13. Controlling party

The company is a wholly owned subsidiary of Beacon Medical Group Limited, a company incorporated in Ireland.

The results are consolidated into the results of Beacon Medical Group Limited, the smallest and largest group company to prepare consolidated accounts. The financial statements are available from the Companies Registration Office, Bloom House, Gloucester Place Lower, Dublin 1.

Beacon Medical Distribution Limited

Notes to the abridged financial statements

For the financial year ended 30 June 2025

14. Approval of financial statements

The board of directors approved these financial statements for issue on

6 January 2026